PGR positive

Our study suggests differential tamoxifen benefit by menopausal status. Improved long-term endocrine therapy prediction in premenopausal patients is needed and could involve molecular markers because standard tumor characteristics cannot predict benefit beyond 10 years.

P2, N=200, Recruiting, Oana Danciu | Trial completion date: Dec 2027 --> Aug 2029 | Trial primary completion date: Dec 2024 --> Aug 2028

This study is the first to document a significant association between long-term exposure to ambient PM2.5 and breast cancer incidence through meta-analysis. Air pollution has a pronounced impact on postmenopausal breast cancer, and the strength of the association between specific air pollutants and breast cancer incidence varies across regions. These findings suggest that long-term exposure to NO2 and PM2.5 may increase the incidence of breast cancer.

P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Phase classification: P1/2 --> P1 | Trial completion date: Mar 2025 --> Jul 2025

P2, N=390, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

P1, N=44, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Apr 2017 --> Sep 2024

We judged that both patients were at intermediate risk of recurrence and administered S-1 in addition to endocrine therapy. Even in cases without axillary lymph node metastasis, this combination of S-1 with endocrine therapy was considered to be a useful treatment option if the criteria of the POTENT trial were met.

Surgery was not possible due to comorbidities, so fulvestrant(500 mg/month)+denosumab(120 mg/month)was started. Furthermore, as the tumor markers were elevated, abemaciclib(300 mg/day)was added, which resulted in a decrease in the tumor markers...During the course of treatment, the tumor markers rose again, so the dose was increased to 250 mg/day, which resulted in a decrease in the tumor markers and good tolerability. At present, 36 months after the start of treatment, long SD has continued, no adverse events of grade 3 or higher have been observed, and the drug has been well tolerated.

Her treatment was adjusted to include Faslodex (fulvestrant) and Verzenio (abemaciclib), followed by the surgical resection of the metastatic lymph node. Understanding dormancy and reactivation mechanisms is essential for guiding clinical decisions. Prioritizing individualized follow-up strategies and refining treatment protocols will be key to improving patient outcomes and maintaining quality of life.

Our findings should be used to guide breast cancer management policies in Morocco. Larger cohort studies are needed to determine the specificity of the breast cancer profile in Morocco as well as the epidemiological risk factors specific to every subtype.

In this cohort study of young adults with breast cancer, we identified a subset of patients who experienced a high degree of financial difficulty persisting into early survivorship. Targeted interventions to mitigate financial toxicity-modifiable factors that include support for the employability or return to work support for those experiencing arm symptoms after treatment-are needed.

P3, N=1684, Active, not recruiting, West German Study Group | Recruiting --> Active, not recruiting

P=N/A, N=288, Recruiting, The First Affiliated Hospital of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University

P2, N=60, Recruiting, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University

P1/2, N=40, Completed, Abramson Cancer Center at Penn Medicine | Phase classification: P=N/A --> P1/2

P3, N=1979, Recruiting, Henan Cancer Hospital | Trial primary completion date: Sep 2024 --> Sep 2025

57.14% (4/7) received adjuvant Letrozole for a minimum of 5 years. The patient with a recurrence score of 24 received adjuvant chemotherapy and developed metastatic 4 years post diagnosis while on Tamoxifen...Genomic tests have resulted in a significant reduction in the number of patients receiving adjuvant chemotherapy. However, a more multifacted approach may be required to tailor treatment decisions incorporating genomic testing, clinicopathological features and individual characteristics with the aim of improving outcomes for patients with hormone receptor positive early breast cancer.

Our study shows that among high genomic risk, node-negative, premenopausal patients, the survival rates are numerically similar between Caucasians and African Americans (AAs) when chemotherapy was administered. However, when chemotherapy was omitted, there were numerical differences in the survival rates within the high-risk RS population. This trend was not observed with the MP cohort.

Only the established Johns Hopkins University calculator demonstrated good performance in correctly stratifying our patients. This highlights the need for further refinement and validation in predictive models across diverse patient populations to optimize medical decisions.

The NPI value is calculated based on tumor size, number of lymph nodes and tumor grade (11), The PREDICT program algorithm was developed from data of the East Anglia Cancer Registry and Information Centre (ECRIC) on patients with primary breast cancer treated in 1999-2003 and provides 5- and 10-year survival estimates with and without adjuvant systemic therapy (hormonal therapy, chemotherapy and trastuzumab) (13)...Although limited by sample size and lack of follow-up, these findings emphasize the value of integrating genomic tools with conventional methods to enhance personalized treatment. Future large-scale studies with follow-up are needed to confirm these results and fully establish the clinical utility of the 70-Gene Signature Assay in Mexican patients.

P1, N=54, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Phase classification: P1/2 --> P1 | Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Apr 2024 --> Dec 2024

P2, N=200, Recruiting, Oana Danciu | Active, not recruiting --> Recruiting

Due to discordant imaging findings, the patient then underwent 18F-FES PET/CT, which demonstrated over 90 metastatic osseous lesions. This study highlights the utility of 18F-FES PET/CT over 18F-FDG PET/CT in diagnosis of metastatic osseous lesions in a patient with metastatic estrogen receptor-positive breast cancer.

Participants must not have received any prior treatment for their current breast cancer, including chemotherapy, immunotherapy, biologic, or hormonal therapy, and must be candidates for doxorubicin, paclitaxel, and durvalumab therapy. No participants are currently ineligible. There have been no Grade 4 or higher adverse events reported among the 26 participants assessed for adverse events.

P2, N=376, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed

P2, N=114, Active, not recruiting, Beth Israel Deaconess Medical Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Jul 2025

This patient had a history of right ER/PR positive HER2 negative stage 1 breast cancer s/p lumpectomy with sentinel lymph node biopsy and radiation plus tamoxifen x6 months in 2017...No right-sided sentinel node was identified. The right breast lesions and the left axillary lymph node metastases are all morphologically similar and showed strong ER expression, the results of which are compatible with spreading to the contralateral axilla.

Most of the improvement in trial outcomes is explained by a greater proportion of women with lower-risk disease entering trials and improved adjuvant treatment. After adjustment, women diagnosed since 2000 have about a fifth lower rate of distant recurrence than the 1990s. Long-term risks of distant recurrence for oestrogen receptor-positive disease remain, but are about a tenth lower now than in our previous report.

In the next phase, we aim to combine transcriptomic information with radiographic features to develop image-based breast cancer risk prediction models. This can aid in individualized breast cancer risk assessment and potentially guide personalized screening, prevention recommendations, and treatment decisions.

P=N/A, N=50, Recruiting, Stanford University | Trial primary completion date: Sep 2024 --> Dec 2024

For a single marker, GATA3 displayed the highest sensitivity. The addition of MMG for hormone receptor-positive breast cancers and GCDFP15 for hormone receptor-negative breast cancers further increased sensitivity. The low proportion of multimarker-positive cells suggested that the coexpression observed with traditional ICC is attributable to intratumoral heterogeneity, not genuine coexpression.

IgA nephropathy with glomerular capillary IgA deposition is known to be resistant to corticosteroid therapy. The favorable clinical course of the rare glomerulopathy following breast cancer treatment suggested a diagnosis of paraneoplastic glomerulopathy secondary to breast cancer in our patient.

P1, N=45, Recruiting, Mayo Clinic | N=33 --> 45

P2, N=620, Recruiting, Fudan University | N=140 --> 620

P1/2, N=255, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025

P2, N=200, Active, not recruiting, Oana Danciu | Recruiting --> Active, not recruiting

Treatment typically follows protocols for female breast cancer, including surgery, chemotherapy, and hormone therapy, with tamoxifen being commonly used. Further research is needed to better understand its pathogenesis and to develop more effective, tailored treatments.

P1/2, N=170, Active, not recruiting, Cyteir Therapeutics, Inc. | Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Jul 2024 --> Dec 2024

P1/2, N=3, Completed, Valerio Therapeutics | Recruiting --> Completed | Phase classification: P1b/2 --> P1/2 | N=115 --> 3 | Trial completion date: Apr 2027 --> Oct 2023 | Trial primary completion date: Dec 2026 --> Oct 2023

P1, N=45, Active, not recruiting, University of Texas Southwestern Medical Center | Trial completion date: Aug 2025 --> Jul 2027 | Trial primary completion date: Sep 2024 --> Jul 2027

P2, N=43, Recruiting, City of Hope Medical Center | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025

P1, N=44, Active, not recruiting, National Cancer Institute (NCI) | Completed --> Active, not recruiting | Trial completion date: Apr 2017 --> Aug 2025